Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy

Abstract

AbstractBackgroundStereotactic body radiation therapy (SBRT) is an effective metastasis‐directed therapy for managing oligometastatic prostate cancer patients. However, it lacks reliable biomarkers for risk stratification. Circulating Tumor Cells (CTC) show promise as minimally invasive prognostic indicators. This study evaluates the prognostic value of CTC in oligorecurrent hormone‐sensitive prostate cancer (orHSPC).MethodsorHSPC patients with 1‐3 nodal and/or bone metastases undergoing SBRT were enrolled (N = 35), with a median follow‐up time of 42.1 months. CTC levels were measured at baseline (T0), 1 month (T1), and 3 months (T2) post‐SBRT using a novel metabolism‐based assay. These levels were correlated with clinical outcomes through Cox‐regression and Kaplan‐Meier analyses.ResultsMedian CTC counts were 5 at T0, 8 at T1, and 5 at T2 with no significant variation over time. Multivariate analysis identified high (≥5/7.5 mL) T0 CTC counts (HR 2.9, 95% CI 1.3–6.5, p = 0.01, median DPFS 29.7 vs. 14.0 months) and having more than one metastasis (HR 3.9, 95% CI 1.8–8.6, p < 0.005, median DPFS 34.1 vs. 10.7 months) as independent predictors of distant progression‐free survival (DPFS). CTC assessment successfully stratified patients with a single metastasis (HR 3.4, 95% CI 1.1–10.2, p = 0.03, median DPFS 42.1 vs. 16.7 months), but not those with more than one metastasis. Additionally, a combined score based on CTC levels and the number of metastases effectively stratified patients.ConclusionThe study demonstrates that hypermetabolic CTC could enhance risk stratification in orHSPC patients undergoing SBRT, particularly in patients with limited metastatic burden, potentially identifying patients with indolent disease who are suitable for tailored SBRT interventions.